Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01073228 · ClinicalTrials.gov registry record · Phase 2
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 409
- Enrollment target
NCT01073228: Completed Phase 2 study, sponsored by FORUM Pharmaceuticals.
NCT01073228 is a Phase 2 study that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 409 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (208% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01073228, a Phase 2 study, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 409 participants
- Enrollment target
Study Summary
This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG EVP-6124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT01073228 record still lists
NCT01073228 is an interventional study that assigns participants to a tested intervention. The registered 409 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (208% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01073228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01073228 about?
NCT01073228 is a clinical study titled "Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease". This study is being conducted to determine the safety and effect on cognitive function of the investigational medication, EVP-6124, in individuals with mild to moderate probable Alzheimer's disease.
What is the current status of trial NCT01073228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 409 participants. The study started on 2010-04. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01073228?
The interventions under investigation include: Placebo (DRUG), EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT01073228?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01073228's enrollment target sits among peer trials
409 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717334 · 409 participants
A Study of Lung Cancer Screening in People With Unexplained Weight Loss
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia